ArticleOral oncology2025
Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
Article in Oral oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early clearance of circulating tumor DNA as a determinant of induction therapy response in human papillomavirus-associated oropharyngeal squamous cell carcinoma.Translational cancer research · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor tissue-modified viral (TTMV) HPV DNA is a sensitive, highly specific biomarker for human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPVOPC). We monitored the kinetics of TTMV responses to induction chemotherapy (IC) or induction chemoimmunotherapy (ICI) and analyzed the predictive implications for treatment outcomes.
methodsPatients with locally advanced HPVOPC with high-risk features were treated with 3 cycles of IC (docetaxel-cisplatin-fluorouracil) or anti-PD1 ICI (docetaxel-cisplatin-Cemiplimab or docetaxel-cisplatin-Pembrolizumab). Depending on clinical trial enrollment, patients were followed by standard- or reduced-dose chemoradiation (CRT) alone or with adjuvant immunotherapy. TTMV testing was done pre-treatment, after each cycle and CRT, and throughout surveillance and analyzed retrospectively.
resultsTwenty-eight subjects (26 male, 13 smokers) had a median pre-treatment TTMV of 1321 fragments (range 27-90770, IQR 200-3217). 10/28 patients reached full TTMV clearance after one IC cycle (IC1), 8/28 after two cycles (IC2), 3/28 after three cycles (IC3), and 1/28 remained TTMV + throughout IC and cleared after CRT. 6/28 did not have complete kinetics (labeled "unknown") due to missing data. All patients were TTMV-negative following CRT. During surveillance, 6/28 patients developed HPVOPC recurrence (1 locoregional, 5 metastatic); of these, 2/6 cleared TTMV after IC2, 2/6 IC3, 1/6 CRT, and 1/6 unknown when he cleared. Rapid clearance after IC1 was associated with having no recurrence (p = 0.046) and lower baseline TTMV (p = 0.049).
conclusionsDelayed TTMV clearance during induction chemotherapy or chemoimmunotherapy strongly predicted systemic failure and may help identify patients requiring more systemic therapy. Although these data are robust, future studies should validate these retrospective, hypothesis-generating findings in larger cohorts.
Indexed as
Identifiers
40834707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.